Narcolepsy Therapeutics: Market Research Report
This report analyzes the Global market for Narcolepsy Therapeutics in US$ Million.
Annual estimates and forecasts are provided for the period 2006 through 2015.
The report profiles 14 companies including many key and niche players such as Arena Pharmaceuticals, Inc., Cephalon, Inc., Evotec AG, Hypnion, Inc., and Jazz Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Annual estimates and forecasts are provided for the period 2006 through 2015.
The report profiles 14 companies including many key and niche players such as Arena Pharmaceuticals, Inc., Cephalon, Inc., Evotec AG, Hypnion, Inc., and Jazz Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.GLOBAL MARKET OVERVIEW
Sleep Disorders Market – A Prelude
Narcolepsy – A Chronic Neurological Sleep Disorder
Narcolepsy Therapeutics Market – A Small, Yet Growing Market
Cephalon’s Provigil – The Market Leader
Provigil and Xyrem Continue to Tussle for Dominance
Xyrem – The Other Approved Treatment for Narcolepsy
Provigil’s Successor, Nuvigil to Retain Cephalon’s Leadership
2.MARKET DYNAMICS
Price Increase of Provigil to Aid Patient Shift to Nuvigil
Concerns Raise Over Safety of Provigil
Cephalon Faces Lawsuit for Suspected Blockage of Provigil’s Generics
Jazz Pharmaceuticals Settles Lawsuit on Xyrem
3.NARCOLEPSY – AN OVERVIEW
Sleep Physiology in Narcoleptics
Etiology
Hereditary
Variants in HLA Genes
Hypocretin Deficiency
Symptoms
Excessive Daytime Sleepiness (EDS)
Cataplexy
Sleep Paralysis
Hallucinations
Automatic Behavior
Frequency and Duration of Sleep Episodes
Diagnosis
Polysomnogram
Multiple Sleep Latency Test (MSLT)
Epworth Sleepiness Scale
Spinal Fluid Analysis
Psychological and Social Effects
4.NARCOLEPSY TREATMENT - A REVIEW
Drug therapy
Treatment for EDS
Modafinil (Provigil)
Select Drugs Commonly Used to Treat EDS - Advantages and Disadvantages
Treatment for Cataplexy
Xyrem: The Only FDA-approved Drug for Cataplexy
Lifestyle Changes and Behavioral Treatment
Alternative Remedies
5.REGULATORY AFFAIRS
Watson Files ANDA for Generic Nuvigil, Cephalon Sues Watson
Cephalon Files Application with US FDA for Nuvigil to Treat Jet Lag
Cephalon Files Suit against Mylan Alleging Patent Infringement
Cephalon Files Patent Infringement Lawsuit Against Teva for Nuvigil
Mitsubishi Tanabe Withdraws NDS for Modafinil
Barr Laboratories Initiates Voluntary Recall of Generic Amphetamine
Cephalon Obtains FDA Clearance to Market Nuvigil for Treating EDS
6.CORPORATE INITIATIVES IN THE NARCOLEPSY MARKET
Nocturna Sleep Centers Signs Deal with Medical Center of McKinney
Cephalon Launches NUVIGIL Tablets
Davie County Hospital Adds New Sleep Laboratory
Addrenex Inks Licensing Agreement with SK Holdings
Graymark Healthcare Purchases Avastra Eastern Sleep Centers Inc.
SDC Holdings Signs Agreement with Medical Center of Plano
Ligand Acquires Neurogen
Cephalon Signs Federal Multi-State Agreement with The State of Utah
Paladin Labs Buys Dexedrine from GlaxoSmithKline
St. Catherine Establishes Sleep Disorders Center
SCOA Takes Over Sleep Holdings
Graymark Healthcare Acquires SDG and Nocturna Sleep
7.FOCUS ON SELECT MARKET PARTICIPANTS
Arena Pharmaceuticals, Inc. (US)
Cephalon, Inc. (US)
Evotec AG (Germany)
Hypnion, Inc. (US)
Jazz Pharmaceuticals, Inc. (US)
8.GLOBAL MARKET ANALYTICS
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 14 (including Divisions/Subsidiaries - 15)
Region/CountryPlayers
The United States
Canada
Japan
Europe
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.GLOBAL MARKET OVERVIEW
Sleep Disorders Market – A Prelude
Narcolepsy – A Chronic Neurological Sleep Disorder
Narcolepsy Therapeutics Market – A Small, Yet Growing Market
Cephalon’s Provigil – The Market Leader
Provigil and Xyrem Continue to Tussle for Dominance
Xyrem – The Other Approved Treatment for Narcolepsy
Provigil’s Successor, Nuvigil to Retain Cephalon’s Leadership
2.MARKET DYNAMICS
Price Increase of Provigil to Aid Patient Shift to Nuvigil
Concerns Raise Over Safety of Provigil
Cephalon Faces Lawsuit for Suspected Blockage of Provigil’s Generics
Jazz Pharmaceuticals Settles Lawsuit on Xyrem
3.NARCOLEPSY – AN OVERVIEW
Sleep Physiology in Narcoleptics
Etiology
Hereditary
Variants in HLA Genes
Hypocretin Deficiency
Symptoms
Excessive Daytime Sleepiness (EDS)
Cataplexy
Sleep Paralysis
Hallucinations
Automatic Behavior
Frequency and Duration of Sleep Episodes
Diagnosis
Polysomnogram
Multiple Sleep Latency Test (MSLT)
Epworth Sleepiness Scale
Spinal Fluid Analysis
Psychological and Social Effects
4.NARCOLEPSY TREATMENT - A REVIEW
Drug therapy
Treatment for EDS
Modafinil (Provigil)
Select Drugs Commonly Used to Treat EDS - Advantages and Disadvantages
Treatment for Cataplexy
Xyrem: The Only FDA-approved Drug for Cataplexy
Lifestyle Changes and Behavioral Treatment
Alternative Remedies
5.REGULATORY AFFAIRS
Watson Files ANDA for Generic Nuvigil, Cephalon Sues Watson
Cephalon Files Application with US FDA for Nuvigil to Treat Jet Lag
Cephalon Files Suit against Mylan Alleging Patent Infringement
Cephalon Files Patent Infringement Lawsuit Against Teva for Nuvigil
Mitsubishi Tanabe Withdraws NDS for Modafinil
Barr Laboratories Initiates Voluntary Recall of Generic Amphetamine
Cephalon Obtains FDA Clearance to Market Nuvigil for Treating EDS
6.CORPORATE INITIATIVES IN THE NARCOLEPSY MARKET
Nocturna Sleep Centers Signs Deal with Medical Center of McKinney
Cephalon Launches NUVIGIL Tablets
Davie County Hospital Adds New Sleep Laboratory
Addrenex Inks Licensing Agreement with SK Holdings
Graymark Healthcare Purchases Avastra Eastern Sleep Centers Inc.
SDC Holdings Signs Agreement with Medical Center of Plano
Ligand Acquires Neurogen
Cephalon Signs Federal Multi-State Agreement with The State of Utah
Paladin Labs Buys Dexedrine from GlaxoSmithKline
St. Catherine Establishes Sleep Disorders Center
SCOA Takes Over Sleep Holdings
Graymark Healthcare Acquires SDG and Nocturna Sleep
7.FOCUS ON SELECT MARKET PARTICIPANTS
Arena Pharmaceuticals, Inc. (US)
Cephalon, Inc. (US)
Evotec AG (Germany)
Hypnion, Inc. (US)
Jazz Pharmaceuticals, Inc. (US)
8.GLOBAL MARKET ANALYTICS
Table 1. World Recent Past, Current & Future Market Analysis for Narcolepsy Therapeutics – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 14 (including Divisions/Subsidiaries - 15)
Region/CountryPlayers
The United States
Canada
Japan
Europe
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
